WO2026032183 - NITROGEN-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/032183
Publication Date
12.02.2026
International Application No.
PCT/CN2025/112330
International Filing Date
04.08.2025
Title **
[English]
NITROGEN-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF
[French]
COMPOSÉ CYCLIQUE FUSIONNÉ CONTENANT DE L'AZOTE, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE
Applicants **
RONGCHANG PHARMACEUTICALS, LTD.
Inventors
BAO, Jianming
WANG, Zhiyong
LIU, Xiaohong
Priority Data
PCT/CN2024/109865
05.08.2024
CN
PCT/CN2025/070469
03.01.2025
CN
PCT/CN2025/103255
25.06.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3844 | |
| EPO | Filing, Examination, Granting | 20325 | |
| Japan | Filing, Examination, Granting | 2214 | |
| South Korea | Filing, Examination, Granting | 2336 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
35,259
Contact Us
Abstract[English]
The present invention discloses nitrogen-containing fused ring compound, pharmaceutical composition and use thereof. The present invention provides a compound represented by formula II, a solvate, a pharmaceutically acceptable salt thereof or a solvate of the pharmaceutically acceptable salt thereof. The compounds of the present disclosure are potent GLP-1 receptor agonists, and are useful to treat diabetes or obesity.[French]
La présente invention concerne un composé cyclique fusionné contenant de l'azote, une composition pharmaceutique et son utilisation. La présente invention concerne un composé représenté par la formule II, un solvate, un sel pharmaceutiquement acceptable de celui-ci ou un solvate du sel pharmaceutiquement acceptable de celui-ci. Les composés de la présente invention sont des agonistes puissants du récepteur GLP-1, et sont utiles pour traiter le diabète ou l'obésité.